KOS AND JERINI SIGN EXCLUSIVE COLLABORATION AND LICENSE AGREEMENT FOR DEVELOPMENT, MARKETING AND DISTRIBUTION OF ICATIBANT IN THE UNITED STATES AND CANADAExclusive Collaboration and License Agreement • November 8th, 2005 • Kos Pharmaceuticals Inc • Pharmaceutical preparations
• Icatibant, in final Phase III clinical trials for hereditary angioedema (HAE), represents next potential new product launch for both companies scheduled for the first half of 2007
